Malignant News and Research

RSS

NeoGenomics launches clinical molecular tests for comprehensive profiling of MDS

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today that it has validated and launched a number of clinical molecular tests for the comprehensive profiling of myelodysplastic syndrome.

25 Jul 2013

Verastem's defactinib gets FDA orphan drug designation for treatment of mesothelioma

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that lead cancer stem cell inhibitor, VS-6063 (defactinib), has received orphan drug designation from the U.S. Food and Drug Administration for use in the treatment of mesothelioma, a rare form of lung cancer.

24 Jul 2013

3-D hydrogel approach to study aggressive and deadly forms of brain cancer

Human glioblastoma multiforme, one of the most common, aggressive and deadly forms of brain cancer, is notoriously difficult to study. Scientists have traditionally studied cancer cells in petri dishes, which have none of the properties of the brain tissues in which these cancers grow, or in expensive animal models.

24 Jul 2013

Findings open new perspectives for research on proteins that control metastasis

In experiments on zebrafish, Freiburg researchers have demonstrated that the same proteins that lead to the formation of metastases in humans also cause the cells to migrate during embryonic development.

24 Jul 2013

Digital versions of standard molecular biology tool to detect common tumor-associated mutation in CSF

Massachusetts General Hospital (MGH) researchers and their colleagues have used digital versions of a standard molecular biology tool to detect a common tumor-associated mutation in the cerebrospinal fluid (CSF) of patients with brain tumors. In their report being published in the open-access journal Molecular Therapy - Nucleic Acids, the investigators describe using advanced forms of the gene-amplification technology polymerase chain reaction (PCR) to analyze bits of RNA carried in membrane-covered sacs called extracellular vesicles for the presence of a tumor-associated mutation in a gene called IDH1.

24 Jul 2013

Understanding cancer at source could improve disease prevention

A new disease is affecting developing countries, deadlier than malaria, AIDS and tuberculosis combined. With changes in lifestyles, cancer is spreading in southern countries.

23 Jul 2013

Absence of Shp-2 enzyme near cartilage cells can lead to multiple benign cartilage tumors in mice

Rhode Island Hospital researchers have found that the absence of the Shp-2 enzyme near specialized cartilage cells can lead to the development of multiple benign cartilage tumors in mice, a model that recapitulates the rare human tumor syndrome metachondromatosis.

20 Jul 2013

Mirror Effect of Immunovative Therapies: A new approach to cancer treatment

Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies Ltd, a biotech company in Israel, describes a new and unique approach to cancer treatment.

20 Jul 2013

NCI awards $1.5M grant to LSUHSC researcher to study role of chronic inflammation in cancer

Yan Cui, PhD, Associate Professor of Microbiology, Immunology, & Parasitology at LSU Health Sciences Center New Orleans and the LSUHSC Stanley S. Scott Cancer Center, has been awarded a $1.5 million grant over five years by the National Cancer Institute to study the role of chronic inflammation in the development and progression of cancer.

19 Jul 2013

New theory challenges orthodox view that cancer develops in each host by mutational accidents

A new way to look at cancer -- by tracing its deep evolutionary roots to the dawn of multicellularity more than a billion years ago -- has been proposed by Paul Davies of Arizona State University's Beyond Center for Fundamental Concepts in Science in collaboration with Charles Lineweaver of the Australian National University.

15 Jul 2013

Researchers develop new tool for comprehensive mapping of cell-cell communication

Researchers at Memorial Sloan-Kettering Cancer Center, together with collaborators in Germany, have developed a new method for identifying the cell of origin of intracellular and secreted proteins within multicellular environments.

11 Jul 2013

Pharmacyclics submits ibrutinib NDA to FDA for two B-cell malignancies

Pharmacyclics, Inc. today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for the investigational oral Bruton's tyrosine kinase inhibitor, ibrutinib, for two relapsed/refractory B-cell malignancy indications: mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma.

10 Jul 2013

Study confirms role of MAPK mutations in pilocytic astrocytomas

Brain cancer is the primary cause of cancer mortality in children. Even in cases when the cancer is cured, young patients suffer from the stress of a treatment that can be harmful to the developing brain. In a search for new target structures that would create more gentle treatments, cancer researchers are systematically analyzing all alterations in the genetic material of these tumors.

10 Jul 2013

Soy protein supplement does not reduce recurrence of prostate cancer post radical prostatectomy

Among men who had undergone radical prostatectomy, daily consumption of a beverage powder supplement containing soy protein isolate for 2 years did not reduce or delay development of biochemical recurrence of prostate cancer compared to men who received placebo, according to a study in the July 10 issue of JAMA.

10 Jul 2013

Mouse study identifies new treatment options for bowel cancer

Researchers have discovered the genetic processes that cause specific types of bowel cancer. Using this knowledge, they identified cancer drugs that target these genes. Their findings offer the opportunity to develop personalised treatment based on a person's genetic profile.

9 Jul 2013

Discovery sheds new light on aggressiveness of certain breast cancers

In a discovery that sheds new light on the aggressiveness of certain breast cancers, Whitehead Institute researchers have identified a transcription factor, known as ZEB1, that is capable of converting non-aggressive basal-type cancer cells into highly malignant, tumor-forming cancer stem cells (CSCs). Intriguingly, luminal breast cancer cells, which are associated with a much better clinical prognosis, carry this gene in a state in which it seems to be permanently shut down.

4 Jul 2013

Study shows activated blood platelets enable cancer cells to penetrate blood vessels

Malignant tumours often spread to remote areas of the body. In the majority of cases, metastases formation develops via the blood vascular system. The blood platelets thereby provide invaluable help to the tumour cells in penetrating new organs.

4 Jul 2013

Study shows smokers, single men more likely to acquire cancer-causing oral HPV

Smokers and single men are more likely to acquire cancer-causing oral human papillomavirus (HPV), according to new results from the HPV Infection in Men (HIM) Study. Researchers from Moffitt Cancer Center, the National Cancer Institute, Mexico and Brazil also report that newly acquired oral HPV infections in healthy men are rare and when present, usually resolve within one year.

3 Jul 2013

Study shows autophagy blockers play a role in treatment of non-small-cell lung cancer

New research from Rutgers Cancer Institute of New Jersey, Princeton University and other collaborators suggests that inactivation of an essential gene responsible for the cell survival process known as autophagy can suppress the growth of non-small-cell lung cancer tumors and render them more benign.

1 Jul 2013

Physical activity and low calorie food may reduce risk of aggressive prostate cancer

Researchers at UCLA's Jonsson Comprehensive Cancer Center (JCCC) have published the first study on adherence to eight World Cancer Research Fund (WCRF) lifestyle recommendations and aggressive prostate cancer that shows a significantly decreased risk of highly aggressive prostate cancer associated with closer adherence to the recommendations.

30 Jun 2013

Malignant News and Research

NeoGenomics launches clinical molecular tests for comprehensive profiling of MDS

Verastem's defactinib gets FDA orphan drug designation for treatment of mesothelioma

3-D hydrogel approach to study aggressive and deadly forms of brain cancer

Findings open new perspectives for research on proteins that control metastasis

Digital versions of standard molecular biology tool to detect common tumor-associated mutation in CSF

Understanding cancer at source could improve disease prevention

Absence of Shp-2 enzyme near cartilage cells can lead to multiple benign cartilage tumors in mice

Mirror Effect of Immunovative Therapies: A new approach to cancer treatment

NCI awards $1.5M grant to LSUHSC researcher to study role of chronic inflammation in cancer

New theory challenges orthodox view that cancer develops in each host by mutational accidents

Researchers develop new tool for comprehensive mapping of cell-cell communication

Pharmacyclics submits ibrutinib NDA to FDA for two B-cell malignancies

Study confirms role of MAPK mutations in pilocytic astrocytomas

Soy protein supplement does not reduce recurrence of prostate cancer post radical prostatectomy

Mouse study identifies new treatment options for bowel cancer

Discovery sheds new light on aggressiveness of certain breast cancers

Study shows activated blood platelets enable cancer cells to penetrate blood vessels

Study shows smokers, single men more likely to acquire cancer-causing oral HPV

Study shows autophagy blockers play a role in treatment of non-small-cell lung cancer

Physical activity and low calorie food may reduce risk of aggressive prostate cancer

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News